logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Akebia Therapeutics, Inc.


USPTO Granted Patents = 32



Trademarks = 5

Forward Citations = 349

Loading Chart...
Loading Chart...

43 inventors (with patents filed for the assignee):

goldMedal James Densmore Copp (13 out of 16 patents)

silverMedal Artem G Evdokimov (11 out of 56 patents)

bronzeMedal Richard Masaru Kawamoto (11 out of 17 patents)

4.  Angelique Sun Boyer (11 out of 14 patents)

5.  Namal Chithranga Warshakoon (11 out of 15 patents)

6.  Kenneth D Greis (10 out of 14 patents)

7.  Shengde Wu (10 out of 13 patents)

8.  Anne Luong (8 out of 8 patents)

9.  Christopher M Lanthier (7 out of 7 patents)

10.  Ann W Newman (7 out of 8 patents)

11.  Boris Gorin (6 out of 31 patents)

12.  John M Janusz (6 out of 36 patents)

13.  Jan Oudenes (5 out of 17 patents)

14.  Craig Edward Dixon (5 out of 9 patents)

15.  Alan Quigbo Lu (4 out of 4 patents)


32 patents:

1. 12419877 - Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof (2025-09-23),
2. 12269802 - Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino] acetic acid (2025-04-08),
3. 11883386 - Prolyl hydroxylase inhibitors and methods of use (2024-01-30),
4. 11857543 - Compositions and methods for treating anemia (2024-01-02),
5. 11844756 - Compositions and methods for treating anemia (2023-12-19),
6. 11713298 - Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid (2023-08-01),
7. 11690836 - Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof (2023-07-04),
8. 11524939 - Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid (2022-12-13),
9. 11426393 - Prolyl hydroxylase inhibitors and methods of use (2022-08-30),
10. 11324734 - Compositions and methods for treating anemia (2022-05-10),
11. 11267785 - Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides (2022-03-08),
12. 11065237 - Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof (2021-07-20),
13. 10738010 - Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides (2020-08-11),
14. 10729681 - Prolyl hydroxylase inhibitors and methods of use (2020-08-04),
15. 10596158 - Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof (2020-03-24),
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney diseases. The company utilizes its proprietary hypoxia-inducible factor (HIF) technology platform to develop novel compounds that regulate oxygen sensing in the body. Akebia aims to improve the lives of patients by providing innovative treatments, especially in the field of anemia and other complications related to kidney disorders.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
32 Patents

#70 in Cambridge, MA

#606 in Massachusetts

#10,245 in US

#20,091 in the World

...
Cambridge, MA, United States of America

Akebia Therapeutics, Inc.

Forward Citations = 349

43 inventors:

goldMedal James Densmore Copp (13 out of 16 patents)

silverMedal Artem G Evdokimov (11 out of 56 patents)

bronzeMedal Richard Masaru Kawamoto (11 out of 17 patents)

4.  Angelique Sun Boyer (11 out of 14 patents)

5.  Namal Chithranga Warshakoon (11 out of 15 patents)

Please report any incorrect information to support@idiyas.com
Loading…